|
Tuesday, 25 October 2011 06:53 |
|
Shares in U.K. drug maker Vectura Group PLC (VEC.LN) fell more than 20% Tuesday after its partner Novartis AG (NOVN.VX) reported delays to the U.S. regulatory approval of key lung drug NVA237. Novartis said U.S. regulators have asked for further clinical data on the drug, an inhaled powder for the treatment of chronic obstructive pulmonary disease, a lung condition known as smoker's lung. |
|
Read more...
|
|
Friday, 14 October 2011 00:27 |
|
 Baxter International Inc. (BAX), the maker of blood products and intravenous drugs, declined 3.1 percent after an analyst said the company may be hurt by health insurer Aetna Inc. (AET)’s decision to favor a rival Grifols SA (GRF) treatment for immune system disorders.
|
|
Read more...
|
|
Monday, 05 September 2011 00:59 |
 SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced it anticipates that it will begin operating under the name Astex Pharmaceuticals, Inc. on September 12, 2011.
|
|
Read more...
|
|
Tuesday, 30 August 2011 00:45 |
 PharMerica Corporation (NYSE:PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that its Board of Directors has adopted a stockholder rights plan (the “Rights Plan”).
|
|
Read more...
|
|
Wednesday, 29 June 2011 01:08 |
 Pfizer Inc (PFE.N) said on Friday it is considering a "strategic transaction" with Icagen Inc (ICGN.O), a tiny biotechnology company in which Pfizer holds a 14.2 cent stake.
|
|
Read more...
|
|
Thursday, 09 June 2011 02:56 |
 OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced the Company has regained compliance with the minimum Market Value of Listed Securities (MVLS) requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5450(b)(2)(A). Consequently, the Company's securities will continue to be listed on The NASDAQ Stock Market (NASDAQ).
|
|
Read more...
|
|
Friday, 15 April 2011 02:12 |
 Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA. The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised.
|
|
Read more...
|
|
Tuesday, 22 March 2011 00:05 |
 Affymax, Inc. (Nasdaq:AFFY), today announced the pricing of an underwritten public offering of 8,474,576 shares of its common stock at a price to the public of $5.90 per share.
|
|
Read more...
|
|
Monday, 14 February 2011 02:59 |
 Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs to reduce scarring, improve wound healing and enhance tissue regeneration today announces that its first EU Phase III trial for Juvista in scar revision surgery (REVISE(TM)) did not meet its primary or secondary endpoints.
|
|
Read more...
|
|
Saturday, 11 December 2010 15:54 |
 Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at $14.35 per share.
|
|
Read more...
|
|
|
Monday, 17 October 2011 00:38 |
 Depomed, Inc. /quotes/zigman/63635/quotes/nls/depo DEPO -25.96% today announced top-line results from BREEZE 3, a Phase 3 trial evaluating the efficacy and safety of Serada(R) (extended-release gabapentin tablets) for menopausal hot flashes.
|
|
Read more...
|
|
Tuesday, 27 September 2011 00:28 |
 Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 12.5% increase in the quarterly dividend rate, from $0.20 per ordinary share to $0.225 per ordinary share.
|
|
Read more...
|
|
Thursday, 01 September 2011 00:36 |
 Icagen, Inc. (Nasdaq:ICGN) announced today that it has sent the following letter to stockholders affirming the Board's recommendation after receiving a letter from Pfizer Inc. (NYSE:PFE) on Friday, August 26, 2011 stating that Pfizer's best and final offer price is $6.00 per share:
|
|
Read more...
|
|
Friday, 12 August 2011 00:04 |
 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Exelbine (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.
|
|
Read more...
|
|
Wednesday, 15 June 2011 01:02 |
 Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders (“Synageva”), and Trimeris, Inc. (NASDAQ: TRMS) (“Trimeris”), announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.
|
|
Read more...
|
|
Tuesday, 24 May 2011 00:09 |
 Targacept, Inc. (NASDAQ: TRGT) announced today the pricing of an underwritten public offering of 3,658,537 shares of its common stock at a price to the public of $20.50 per share.
|
|
Read more...
|
|
Thursday, 14 April 2011 00:20 |
|
 NPS Pharmaceuticals Inc. (NPSP) said Monday it plans to sell at least 9 million shares in an offering to the public, making it the latest company looking to tap equity markets to raise capital.
|
|
Read more...
|
|
Tuesday, 15 February 2011 00:19 |
 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the pricing of a previously announced underwritten public offering of 6,000,000 shares of its common stock, offered at a price to the public of $11.25 per share.
|
|
Read more...
|
|
Thursday, 13 January 2011 13:06 |
 Genzyme Corp. (NASDAQ: GENZ) reported today that discussions between its financial advisors and financial advisors for Sanofi-Aventis are continuing and have expanded to include representatives of both companies.
|
|
Read more...
|
|
Saturday, 23 October 2010 15:14 |
 Abbott Laboratories, a maker of drugs and medical devices, fell after it reported third-quarter sales that missed analysts’ estimates.
|
|
Read more...
|
|
